Navigation Links
International collaboration finds 11 new Alzheimer's genes to target for drug discovery
Date:10/27/2013

MIAMI -- University of Miami Miller School of Medicine researchers played a key role in the largest international Alzheimer's disease genetics collaboration to date, which identified 11 new regions of the genome that contribute to late-onset Alzheimer's disease, doubling the number of potential genetics-based therapeutic targets to investigate. Published October 27 in Nature Genetics, the study gives a broader view of the genetic factors contributing to Alzheimer's and expands the understanding of the disease to new areas, including the immune system, where a genetic overlap with other neurodegenerative diseases, including multiple sclerosis and Parkinson's disease, was identified.

In 2011, the world's four largest research consortia on the genetics of Alzheimer's disease joined efforts to discover and map the genes that contribute to Alzheimer's, forming the International Genomics of Alzheimer's Project (IGAP). The team collected genetic information from 25,500 Alzheimer's disease patients and 49,038 controls from 15 countries to perform this two-stage meta-analysis that resulted in the discovery of 11 new genes in addition to those already known, and the identification of 13 other genes, yet to be validated.

Margaret A. Pericak-Vance, Ph.D., the Dr. John T. Macdonald Foundation Professor of Human Genomics and Director of the John P. Hussman Institute for Human Genomics at the Miller School, and Lindsay A. Farrer, Ph.D., from Boston University, led the analysis teams for the American Alzheimer's Disease Genetics Consortium, which includes nearly all of the nation's researchers working on the genetics of Alzheimer's, as well as many investigators and resources of the 29 federally funded Alzheimer's Disease Centers.

Several of the genes the researchers identified confirmed known biological pathways of Alzheimer's disease, including the role of the amyloid (SORL1, CASS4) and tau (CASS4, FERMT2) pathways. Newly discovered genes involved in the immune response and inflammation (HLA-DRB5/DRB1, INPP5D, MEF2C) reinforced a pathway implied by previous work (on CR1, TREM2). Additional genes related to cell migration (PTK2B), lipid transport and endocytosis (SORL1) also were confirmed, and new hypotheses emerged related to hippocampal synaptic function (MEF2C, PTK2B), the cytoskeleton and axonal transport (CELF1, NME8, CASS4), as well as myeloid and microglial cell functions (INPP5D).

One of the more significant new associations was found in the HLA-DRB5/DRB1 region, one of the most complex parts of the genome, which plays a role in the immune system and inflammatory response. It also has been associated with multiple sclerosis and Parkinson's disease, suggesting that the diseases where abnormal proteins accumulate in the brain may have a common mechanism involved, and possibly a common drug target.

"The discovery of novel pathways is very encouraging considering the limited success of Alzheimer's disease drugs tested so far," Pericak-Vance said. "Our findings bring us closer toward identifying new drug targets for Alzheimer's and other neurodegenerative diseases. We'll continue to expand and analyze our data set with this incredible group so that we can better understand the genetic influences on this devastating disease, and find new medical and therapeutic interventions."


'/>"/>

Contact: Alexandra Bassil
a.bassil@miami.edu
305-284-1092
University of Miami
Source:Eurekalert

Related biology news :

1. PETA and its international affiliates launch not-for-profit international science company
2. Stepping up the Pace: 20th International AIDS Conference (AIDS 2014) theme selected
3. International Niels Bohr Conference: An open world
4. Celiac research to highlight international symposium
5. New research on potential avocado health benefits presented at International Congress of Nutrition
6. International experts to explore new wonderdrug at conference
7. International Rett Syndrome Foundation chief science officer receives prestigious military awards
8. SmartMove, Inc. receives $200,000 grant from the Colorado Office of Economic Development and International Trade
9. Researchers describe potential for MERS coronavirus to spread internationally
10. UChicago Celiac Disease Center to host international symposium
11. MARC travel awards announced for the GSA: 19th International C. elegans Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider ... introduction of Onitor Track, an innovative biometric data-driven program ... showcasing this month at the 2017 Consumer Electronics Show ... In the U.S., the World Health Organization ... than two-thirds of adults who are overweight or obese. ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... ... 2017 , ... Each year, Crain’s Detroit Business News ranks the most innovative ... patent estate of a company, its impact and significance, and the likelihood of bringing ... in technologies that transform energy sources such as low dose X-ray and convert them ...
(Date:1/12/2017)... Colo (PRWEB) , ... January 12, 2017 , ... ... then to targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few ... describes a new drug combination that has stabilized Rosendahl’s disease and increased both ...
(Date:1/12/2017)... PORTLAND, Oregon and Pune, India , January 12, 2017 ... In vitro Toxicity Testing Market by Type and End Users - Global Opportunity Analysis ... reach $7,813 million by 2022 from $2,921 million in 2015, growing at a CAGR ... ... Allied Market Research Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase ... show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ ... treatment regimens. Twenty-seven percent of these heavily pretreated patients saw clinical benefit from ...
Breaking Biology Technology: